Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience

Abstract

This retrospective study aimed to describe the Hellenic experience on the use of brentuximab vedotin (BV) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) given within its indication. From June 2011 to April 2015, ninety-five patients with R/R HL, who received BV in 20 centers from Greece, were analyzed. Their median age was 33 years, and 62% were males… (More)
DOI: 10.1002/hon.2383

8 Figures and Tables

Topics

  • Presentations referencing similar topics